Stock Ratings / Health Care / ALLO / dividends

AUTL (25) PROK (44) EDIT (37) CCCC (27) ⌘ Pro Terminal →

Allogene Therapeutics Inc. (ALLO) Dividend Safety Gauge & 10-Year DRIP Compounder

Q: Does ALLO pay a dividend and is it safe?

Allogene Therapeutics Inc. (ALLO) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

$1.25 -3.85% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Allogene Therapeutics Inc. (ALLO) carries a Roarable Rating of D- (Sell) with 38/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $431.9M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-8.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ALLO)Realized 20D OHLCV Swing Band: ±12.5%

CASH DIVIDEND + BUYBACK YIELD

1.8% Total Yield

0% Cash ($0.00/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (6.8% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $19,307

Est. Year-10 Shareholder Yield: $348/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.7K

Yr 1

$11.4K

Yr 2

$12.2K

Yr 3

$13.0K

Yr 4

$13.9K

Yr 5

$14.8K

Yr 6

$15.8K

Yr 7

$16.9K

Yr 8

$18.1K

Yr 9

$19.3K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ALLO)

✓Walkthrough of ALLO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ALLO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -41.31%▼ DESCENDING CHANNEL

2026-10-30O $1.24H $1.26L $1.16C $1.25VOL 9.76M

RES: $2.11SUP: $1.12SMA50: $1.62SMA200: $1.98

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ALLO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ALLO Butterfly Map → + Track ALLO →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ALLO today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ALLO. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ALLO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ALLO)

Health Care Rank #708 of 1016 ⚔️ AUTL vs ALLO Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ALLO vs. AUTL, PROK, EDIT, CCCC)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Allogene Therapeutics Inc. (ALLO) ranks #708 by composite RQD confidence (38/100, grade D-) and #469 by equity capitalization ($431.9M). Within this direct 5-issuer industry benchmark cohort, ALLO leads on earnings valuation at N/A trailing P/E, while ALLO leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. PROK currently holds the highest overall quantitative score in the immediate peer group at 44/100 (D) compared with ALLO at 38/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ALLO ACTIVE Allogene Therapeutics Inc.	D-	38/100	—	—	-35.0%	-3.85%	$431.9M	Benchmark Subject
AUTL Autolus Therapeutics plc	E	25/100	—	-27.8%	-35.0%	-3.07%	$420.5M	/autl-vs-allo →
PROK ProKidney Corp. (Class A)	D	44/100	—	—	-35.0%	-3.29%	$444.4M	/prok-vs-allo →
EDIT Editas Medicine Inc.	D-	37/100	—	—	-35.0%	-0.68%	$450.0M	/edit-vs-allo →
CCCC C4 Therapeutics Inc.	E	27/100	—	—	-35.0%	-2.80%	$406.0M	/cccc-vs-allo →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001737287

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Allogene Therapeutics Inc. (ALLO) reported GAAP revenue of $0 (-100.0% vs. FY2024 revenue of $22.0K , and -100.0% cumulative change since FY2023) , GAAP net income of -$190.9M, operating cash flow of -$149.2M, and free cash flow of -$149.6M (+25.6% YoY). On the balance sheet, ALLO closed FY2025 with $415.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$190.9M	-$149.2M	-$149.6M	$415.9M	—
FY2024 (FY)	2024-12-31	$22.0K	-$257.6M	-$200.3M	-$201.0M	$548.7M	—
FY2023 (FY)	2023-12-31	$95.0K	-$327.3M	-$237.7M	-$237.7M	—	—

3. ALLO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ALLO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Allogene Therapeutics Inc. (NASDAQ: ALLO) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $1.25 (-3.85% 1D, market cap $431.9M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, ALLO ranks #708 in composite RQD confidence.

How does ALLO compare to AUTL and PROK in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), ALLO carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, AUTL (Autolus Therapeutics plc) holds a E grade (25/100 RQD, P/E N/A, ROIC -35.0%, cap $420.5M) and PROK (ProKidney Corp. (Class A)) posts a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $444.4M). Among the 5-stock peer group, ALLO leads on earnings multiple (N/A) while ALLO leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ALLO?

Per ALLO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001737287), Allogene Therapeutics Inc. generated $0 in revenue (-100.0% YoY), -$190.9M in net income, and -$149.6M in free cash flow against $415.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ALLO trading relative to its 50-day, 200-day, and 52-week technical levels?

ALLO last traded at $1.25 (-3.85% on volume of 7,714,612 shares), positioning the stock -22.84% below its 50-day simple moving average ($1.62) and -36.87% below its 200-day simple moving average ($1.98). Across its 52-week range of $1.04 to $4.46, ALLO sits at the 6.1% percentile with a 14-day RSI of 29.3 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.09 to $1.41).

ALLO Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does ALLO pay a dividend and is it safe?

Allogene Therapeutics Inc. (ALLO) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: ALLO RQD Cockpit ALLO 12M Forecast ALLO Earnings & Move ALLO Dividends & DRIP ALLO Insiders & 13F ALLO Whale Options ALLO Profit Sankey ALLO News & Why